Prediction: My Top 2 Stocks to Buy Now Will Outperform the Stock Market Over the Next Decade

The central risk in both stories is not demand but the conversion of demand into durable, incremental cash earnings. For Amazon, AI capacity spending can support AWS growth while simultaneously raising depreciation and risking underutilized infrastructure if customer workloads or monetization lag. The key read-through is not headline cloud growth alone: track AWS operating income, capex, depreciation, and capacity utilization. Microsoft and Google are the relevant competitive checks; aggressive capacity buildout across providers could pressure returns even if the market expands.

For Eli Lilly, the upside case depends on sustained access and net economics, not just patient interest. Oral uptake could broaden the addressable pool, but verify regulatory status, real-world persistence, supply, payer coverage, and realized pricing. Novo Nordisk is the most direct competitive benchmark; reimbursement expansion may increase volume while also strengthening payer leverage.

Near term (days), this article adds little beyond an already bullish narrative; without valuation and positioning data, chasing either name is not justified. Over 1–3 months, earnings disclosures on AWS returns and Lilly’s launch/access metrics are the relevant catalysts. Over 6–18 months, Amazon’s capital productivity and Lilly’s competitive, reimbursement, and supply durability matter most. The contrarian point: strong secular demand does not guarantee attractive shareholder returns if investment intensity or pricing absorbs the gains.